# Leerink Partners

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/leerink-partners-company
Canonical HTML page: https://getbiobrief.com/entity/leerink-partners-company

## Timeline

- **2026-08-14**: Earnings release — Replimune Group reported ($0.72) EPS, missing the ($0.69) Zacks consensus by $0.03. Stock opened at $14.97, down $0.22.
- **2026-08-10**: Insider sales — CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
- **2026-08-07**: Wedbush upgrade — Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
- **2026-08-04**: Leerink upgrade — Leerink Partners upgraded Replimune Group from market perform to outperform and raised its price target from $11.00 to $17.00.
- **2026-06-30**: BMO upgrade — BMO Capital Markets raised Replimune Group from underperform to outperform with a $16.00 price target.
- **2026-05-23**: Wall Street Zen upgrade — Wall Street Zen upgraded Replimune Group from strong sell to sell.

## Recent coverage (2 stories)

### Replimune's $1.26B Market Cap Faces EPS Miss as Analysts Boost Targets
2026-08-16 16:18:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Full story: https://getbiobrief.com/story/replimune-earnings-miss-biotech-pipeline

### SGP Hits $17.56 Low: 156% Upside to $45 Analyst Target
2026-08-10 05:23:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Full story: https://getbiobrief.com/story/spyglass-pharma-52-week-low-156-percent-upside-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.